What are treatment options for lung cancer

Treatment Options for Lung Cancer

Lung cancer treatment depends on several important factors that your oncology team will evaluate, including the type of lung cancer (non-small cell or small cell), the stage (how far it has spread), and specific biomarkers (genetic characteristics of your tumor).

Understanding the Two Main Types

1. Non-Small Cell Lung Cancer (NSCLC)

This is the most common type, accounting for about 85% of lung cancers. According to NCCN Guidelines, treatment approaches include:

For Early-Stage Disease:

• Surgery to remove the tumor (lobectomy or pneumonectomy)
• Stereotactic body radiation therapy (SBRT) - a highly precise radiation treatment for patients who cannot have surgery
• Adjuvant therapy (treatment after surgery) may include chemotherapy or targeted therapy to reduce recurrence risk

For Metastatic NSCLC: The NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer emphasize that treatment selection depends heavily on biomarker testing, including:

• PD-L1 expression levels (a protein that affects immune response)
• Gene mutations like EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, and NTRK
• Immunotherapy (pembrolizumab, nivolumab, atezolizumab, cemiplimab, or durvalumab) - often combined with chemotherapy
• Targeted therapies - medications designed to attack specific genetic changes in cancer cells
• Chemotherapy - typically platinum-based combinations with drugs like pemetrexed or paclitaxel

Maintenance Therapy: According to NCCN guidelines, if initial treatment works well, you may transition to maintenance therapy to help prolong the time before cancer worsens. Options include continuing some of your first-line medications like pembrolizumab, atezolizumab, or pemetrexed.

2. Small Cell Lung Cancer (SCLC)

This type grows more quickly and is treated differently. The NCCN SCLC Guidelines describe two main categories:

Limited-Stage SCLC (confined to one area of the chest):

• Concurrent chemoradiation - chemotherapy (typically cisplatin or carboplatin + etoposide) given at the same time as radiation therapy (Category 1 recommendation)
• Durvalumab consolidation therapy - After completing chemoradiation without disease progression, durvalumab immunotherapy for up to 24 months significantly improves survival (median overall survival: 55.9 months vs. 33.4 months with placebo, according to the ADRIATIC trial)
• Prophylactic cranial irradiation (PCI) - radiation to the brain to prevent cancer spread, given before durvalumab if both are planned

Extensive-Stage SCLC (spread beyond one lung area):

• Combination chemotherapy plus immunotherapy as preferred first-line treatment
• Radiation therapy to the brain if metastases are present, or to other symptomatic sites
• Systemic therapy remains the primary treatment approach

Important Questions to Ask Your Oncology Team

1. What specific type and stage of lung cancer do I have?
2. Has biomarker/molecular testing been done on my tumor? What were the results?
3. Based on my specific tumor characteristics, which treatment approach do you recommend and why?
4. Am I a candidate for immunotherapy or targeted therapy?
5. What are the goals of treatment in my case - cure, control, or symptom management?
6. If I have metastatic disease, what is the plan for first-line treatment and potential maintenance therapy?
7. Are there clinical trials available that might be appropriate for my situation?
8. What side effects should I expect, and how can they be managed?

How Doctors Make Treatment Decisions

Oncologists follow a systematic approach:

1. Determine the cancer type through biopsy and pathology review
2. Stage the cancer using imaging (CT, PET scans) to see extent of spread
3. Perform biomarker testing to identify targetable mutations or PD-L1 levels
4. Assess your overall health (performance status) and ability to tolerate treatment
5. Match treatment options to your specific cancer characteristics
6. Consider your preferences and quality of life goals

Important Context

Your specific treatment plan must be determined by your oncology team based on your complete clinical picture, including factors like:

• Exact tumor location and size
• Lymph node involvement
• Presence of metastases
• Your overall health and lung function
• Previous treatments (if any)
• Your personal preferences and goals

The information above represents general treatment categories that exist in medical practice. However, lung cancer treatment is highly individualized, and what works best varies significantly from patient to patient.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Small Cell Lung Cancer (Version 2.2026), NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer (2024)